Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nealand Willingham

Podiatrist Waco, TX Doctor of Podiatric Medicine

NPI 1942422738 CMS profile 223765

201 Colonnade Pkwy, Suite 100, Waco, TX 76712

Open in the dashboard

General payments

$4,397

117 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nealand Willingham of Waco, TX is reported in the CMS Open Payments database as having received $4,397 across 117 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $857 34
2024 General $1,773 52
2023 General $201 4
2022 General $247 4
2021 General $521 7
2020 General $289 8
2019 General $508 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nealand Willingham
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Nealand Willingham were reported at $857. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Nealand Willingham Podiatrist median Middle half National median
2019 $508 $196 $72–$601 $163
2020 $289 $118 $38–$335 $114
2021 $521 $169 $57–$573 $132
2022 $247 $220 $74–$782 $149
2023 $201 $208 $71–$635 $160
2024 $1,773 $237 $87–$681 $164
2025 $857 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $2,929 67 payments
  2. DePuy Synthes Sales Inc. $145 2 payments
  3. Horizon Therapeutics plc $143 7 payments
  4. Paragon 28, Inc. $137 1 payment
  5. Arthrosurface Incorporated $109 1 payment
  6. Integra LifeSciences Corporation $79 2 payments
  7. Paratek Pharmaceuticals, Inc. $75 3 payments
  8. Treace Medical Concepts, Inc. $70 3 payments
  9. Bioventus LLC $64 3 payments
  10. Averitas Pharma Inc. $60 2 payments
  11. Other $584 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,087 115 payments
  2. Education $310 2 payments
Products named General payments · program years 2019–2025
  1. ORTHOLOC 2 LAPIFUSE $483 8 payments
  2. ORTHOLOC 3DI CROSSCHECK $375 3 payments
  3. INBONE $358 4 payments
  4. 7 X 23MM CITRELOCK IMPLANT $357 6 payments
  5. ANCHORAGE $314 6 payments
  6. FIXOS $243 2 payments
  7. ACTISHIELD CF $207 3 payments
  8. VARIAX $205 2 payments
  9. PROSTEP MICA $200 3 payments
  10. PROSTEP $173 3 payments
  11. Other $3,928 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$63,838

Of which drugs: $54

Medicare patients

305

Average age 75

Services billed

1,395

167 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 48%
Ischemic heart disease 37%
Chronic kidney disease 26%
Atrial fibrillation 24%
Depression 19%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 15 74 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $44
$44 — —
KRYSTEXXA
  • Amgen Inc. $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

117 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record